This Article Full Text Full Text (PDF) All Versions of this Article: 1078-0432.CCR-06-1692v1 13/8/2354    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, J.-C. Articles by Chevrette, M. Search for Related Content PubMed PubMed Citation Articles by Wang, J.-C. Articles by Chevrette, M.

Down-Regulation of CD9 Expression during Prostate Carcinoma Progression Is Associated with CD9 mRNA Modifications

Authors' Affiliations: ¹ McMaster University Medical Centre, Hamilton, Ontario, Canada; ² Departments of Pathology and Surgery (Division of Urology), McGill University, Hôpital du Sacré-Coeur de Montréal; ³ Division of Urology, Department of Surgery, McGill University; ⁴ The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada; ⁵ University of Western Ontario, London, Ontario, Canada; and ⁶ Ecopia BioSciences, Inc. Ville Saint-Laurent, Quebec, Canada

Requests for reprints: Mario Chevrette, The Research Institute of the McGill University Health Centre, 1650 Cedar Avenue, Montreal, Quebec, Canada H3G 1A4. Phone: 514-934-1934 ext. 44278; Fax: 514-934-8261; E-mail: mario.chevrette{at}mcgill.ca.

Purpose: Cluster-of-differentiation antigen 9 (CD9) protein, a member of the tetraspanin family, has been implicated in carcinogenesis of various human tumors. Although decreased expression of the CD82 tetraspanin protein, a close CD9 relative, is associated with prostate cancer progression, CD9 expression has not been analyzed in this malignancy.

Experimental Design: CD9 expression in human prostatic adenocarcinoma was analyzed by immunohistochemistry on 167 primary tumors and 88 lymph node or bone metastases. CD9 cDNA was sequenced from two human prostate cancer cell lines, prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia (PIN), and normal prostatic tissues.

Results: Although CD9 was detected in the epithelium of normal prostatic tissues, reduced or loss of CD9 expression within neoplastic cells was observed in 24% of 107 clinically localized primary adenocarcinomas, 85% of 60 clinically advanced primary adenocarcinomas, 85% of 65 lymph node metastases, and 65% of 23 bone metastases. Difference in CD9 expression between clinically localized and advanced diseases was highly significant (P < 1 x 10^–7). Whereas there was no alteration of CD9 cDNA in normal tissues, all PC-3–derived cell lines, one PIN, and four prostatic adenocarcinomas harbored deletions in their CD9 cDNAs. Recurring CD9 point mutations were also found in PC-3M-LN4 cells, one PIN, and seven prostatic adenocarcinomas.

Conclusions: CD9 expression is significantly reduced and even lost during prostate cancer progression. Moreover, deletions and mutations of the CD9 mRNA may be associated with loss of protein expression observed in tumor cells. Our data suggest that CD9 inactivation may play an important role in prostate cancer progression.

This article has been cited by other articles:

				C. Espenel, E. Margeat, P. Dosset, C. Arduise, C. Le Grimellec, C. A. Royer, C. Boucheix, E. Rubinstein, and P.-E. Milhiet Single-molecule analysis of CD9 dynamics and partitioning reveals multiple modes of interaction in the tetraspanin web J. Cell Biol., August 25, 2008; 182(4): 765 - 776. [Abstract] [Full Text] [PDF]